Atossa Therapeutics (NASDAQ:ATOS) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. Separately, Cantor Fitzgerald began coverage on shares of Atossa Therapeutics in a report on Friday, September 8th. They set an overweight rating and a $5.00 price objective on the stock. […]

Leave a Reply

Your email address will not be published.

Previous post JMP Securities Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $38.00
Next post BMO Capital Markets Cuts BSR Real Estate Investment Trust (TSE:HOM.UN) Price Target to C$13.50